Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema

Abstract

Purpose: To estimate the utilization of bevacizumab and to monitor disease in patients with the branch or central retinal vein occlusion (BRVO/ CRVO) and diabetic macular edema (DME) in clinical practice. Material and methods: This hospital-based prospective study comprised 102 patients with macular edema with DME and RVO. Intravitreal injection of 1.25 mg/0.05ml Bevacizumab was administered following standard surgical protocol. All eyes were bi-microscopically examined preoperatively and post-operatively. Results: As per the optical coherence tomography (OCT) results of Central Foveal Thickness (CFT), the amount of CFT in DME patients reduced to 278.20 ± 68.91(initial: 511.02 ± 131.92); in BRVO patients, it was reduced to 219.04 ± 53.61 (initial: 425.83± 151.68); and in CRVO patients, it was reduced to 292.14 ± 46.99 (initial: 598.71 ± 87.27) after the injection at the end of 1 year. There was signifi cant difference observed between the initial and end of follow-up CFT (p